pc 버전으로 이동 중 [시장보고서]세계의 바이오의약품 수탁 제조 시장 예측(-2028년) : COVID-19의 영향과 분석 - 제품별, 서비스별, 원료별, 지역별
세계의 바이오의약품 수탁 제조 시장 예측(-2028년) : COVID-19의 영향과 분석 - 제품별, 서비스별, 원료별, 지역별
Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product ; Service, and Source, and Geography
상품코드 : 1064208
리서치사 : The Insight Partners
발행일 : 2022년 02월
페이지 정보 : 영문 211 Pages
US $ 4,550 ₩ 5,662,000
PDF (Single User License)
US $ 6,550 ₩ 8,150,000
PDF (Site License)
US $ 8,550 ₩ 10,639,000
PDF (Enterprise License)


한글목차

세계의 바이오의약품 수탁 제조 시장 규모는 2021년에 157억 3,504만 달러를 기록했습니다. 시장은 2021-2028년간 8.5%의 CAGR로 확대되고, 2028년에는 278억 6,850만 달러에 달할 것으로 예측됩니다.

제약 기업에 의한 아웃소싱 증가는 시장 성장을 촉진하는 가장 중요한 요인의 하나가 되고 있습니다. 생산능력 과잉 위험을 경감하기 위해서 제조 아웃소싱 수요가 지속적으로 높아지고 있습니다. 바이오의약품 기업과 수탁제조 기업의 계약 건수 증가는 바이오의약품 수탁 제조 시장의 시장 규모 확대를 나타내고 있습니다.

세계의 바이오의약품 수탁 제조(Biopharmaceutical Contract Manufacturing) 시장에 대해 조사했으며, 시장 개요와 함께 제품별, 서비스별, 원료별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 서론

제2장 바이오의약품 수탁 제조 시장 - 중요한 포인트

제3장 조사 방법

제4장 바이오의약품 수탁 제조 - 시장 상황

제5장 바이오의약품 수탁 제조 시장 - 주요 시장 역학

제6장 바이오의약품 수탁 제조 시장 - 세계 분석

제7장 바이오의약품 수탁 제조 시장 분석 - 제품별

제8장 바이오의약품 수탁 제조 시장 - 서비스별

제9장 바이오의약품 수탁 제조 시장 - 원료별

제10장 바이오의약품 수탁 제조 시장 - 지역 분석

제11장 바이오의약품 수탁 제조 시장에 대한 COVID-19 팬데믹의 영향

제12장 바이오의약품 수탁 제조 시장 - 업계 상황

제13장 기업 개요

제14장 부록

KSM 22.03.21
영문 목차

영문목차

The biopharmaceutical contract manufacturing market is projected to reach US$ 27,868.50 million by 2028 from US$ 15,735.04 million in 2021; it is expected to grow at a CAGR of 8.5% from 2021 to 2028. The rising outsourcing by pharmaceutical companies is one of the most key factors driving the growth of the market. A few years ago, the contract manufacturing industry was a niche service market offering additional manufacturing capacity or specific services to pharmaceutical companies. The rise of CMOs was fueled by the increasing number of drug manufacturing failures. In the past, pharmaceutical companies had undertaken manufacturing facilities to develop innovative drugs. However, to reduce the risk of overcapacities, the demand for manufacturing outsourcing has continuously risen. Recently, Revolo Biotherapeutics entered into a partnership with contract development and manufacturing organization (CDMO)-Northway Biotech-to manufacture Revolo's binding immuno-regulatory protein 1805. The partnership included services from cell line development to manufacturing protein with quality assurance and regulatory compliance support. Similarly, Gland Pharma has been manufacturing Remdesivir for four companies, including Mylan, since 2021. Also, the organization increased its manufacturing quotas due to high demand from the companies. In 2019, Samsung Biologics and GI Innovation signed a contract for immunochemotherapy. Under this agreement, Samsung Biologics was providing services ranging from f-cell lines development to production of Phase-I drug substances. The increasing number of contracts between biopharmaceutical companies and contract manufacturing companies shows an increasing market size for the biopharmaceutical contract manufacturing market.

The global biopharmaceutical contract management market is bifurcated on the basis of product, service, and source. Based on product, the market is segmented into biologics and biosimilar. The biologics segment would account for the largest market share during 2021-2028. Biologics are expected to see robust growth due to the various products under the segment, such as monoclonal antibodies, recombinant proteins, vaccines, and others. Biologics have an increasing demand with increasing research and developmental activities to develop new drug products for chronic indications. The COVID-19 pandemic is also expected to drive the growth of the biologics segment with the demand for vaccines for the virus rising. Also, monoclonal antibodies are needed for various chronic illnesses of metabolic, infectious, neurological, and other origins.

By service, the biopharmaceutical contract management market is segmented into process development, fill and finish operations, analytical and quality control studies, and packaging. The process development segment is expected to hold the largest share of the market during the forecast period due to highest investments in process development for production of any biopharmaceutical. The focus on pilot to commercial scale-up process development, cell line development, and other processes are expected to create growth opportunities for process development segment. The segment is further divided into downstream and upstream processing with downstream processing holding the larger share as downstream processing involves a larger amount of products being developed. The analytical and quality control studies segment is expected to have the largest growth rate.

By source, the biopharmaceutical contract management market is segmented into mammalian and microbial-based biologics/non-mammalian. The mammalian segment is expected to hold a larger share of the market as mammalian sources of cells are more commonly used in the industry and can develop a larger range of products compared to microbial-based biologics/non-mammalian sources.

The World Health Organization (WHO), Association of Clinical Research Organizations (ACRO), European Federation of Pharmaceuticals Industries Associations (EFPIA), and Pharmaceutical Research and Manufacturers of America (PhRMA) are among the primary and secondary sources referred to while preparing the report on the biopharmaceutical contract management market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the biopharmaceuticals contract manufacturing market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global biopharmaceuticals contract manufacturing market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

2. Biopharmaceutical Contract Manufacturing Market - Key Takeaways

3. Research Methodology

4. Biopharmaceutical Contract Manufacturing - Market Landscape

5. Biopharmaceuticals Contract Manufacturing Market - Key Market Dynamics

6. Biopharmaceutical Contract Manufacturing Market - Global Analysis

7. Biopharmaceuticals Contract Manufacturing Market Analysis - By Product

8. Biopharmaceuticals Contract Manufacturing Market - By Service

9. Biopharmaceuticals Contract Manufacturing Market - By Source

10. Biopharmaceutical Contract Manufacturing Market - Geographic Analysis

11. Impact of COVID-19 Pandemic on Biopharmaceutical Contract Manufacturing Market

12. Biopharmaceutical Contract Manufacturing Market - Industry Landscape

13. Company Profiles

14. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기